Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Sábháilte in:
Príomhchruthaitheoirí: | , , , , , , , , , , , , , |
---|---|
Formáid: | Alt |
Teanga: | Béarla |
Foilsithe / Cruthaithe: |
Philipps-Universität Marburg
2023
|
Ábhair: | |
Rochtain ar líne: | An téacs iomlán mar PDF |
Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Bí ar an gcéad duine le trácht a dhéanamh!